People seem ashamed to say they have/ are diagnosed with/survived #colorectalcancer. Somehow it is a shameful thing… We cannot raise awareness about CRC if we can only whisper *colorectal* #crcsm #TheNewFaceOfCRC #crc45andunder 1/7

Why fundamental research is fundamental to progress, seeding major breakthroughs Editorial @Nature this week And 7 basic science discoveries that changed the world https://t.co/0YrKabc7ff https://t.co/SM11QSJhWz

👀this🧐thoughtful piece by Dr. @gagan_brar24 on utility of #ctDNA🩸🧬 in non-metastatic rectal #cancer. As we talk about organ sparing approaches, a number of scenarios to keep in mind👇🏽. 💡ctDNA “origin”💦 would be of value in these circumstances. @OncoAlert @OncJournal📚🗞️

DPYD testing is back in the news for Capecitabine and 5FU! What to do and how to dose reduce if you see an intermediate or poor metabolizer? #gism #OncTwitter #MedTwitter #bcsm

@DaisukeKotani The preliminary results from SPRING-01 sound promising, especially with the significant pCR rate improvement compared to the TORCH-E study. However, as you mentioned, the long-term outcomes like DFS will be crucial to determine the true efficacy and potential benefits of the

SPRING-01: rP2 of SCRT followed by CAPOX w/ or w/o sintilimab for locally advanced rectal cancer (ASCO 2025) ✅More patients with high-risk factors (cT4, cN+, EMVI+, and/or MRF+) than TORCH-E study ✅pCR: 59% vs 33%, p=0.015 👉Promising, but need long-term outcomes including DFS

👇🏽This is an excellent read 📕 📖 🔖 if you get a chance @JCO_ASCO #TumorBoardTuesday

Stunning cover of @CellRepMed by @Ella_Maru on this “super centenarian” paper by @ManelEsteller, underscoring the duality of aging in extremely long lived individuals. https://t.co/iTCpEVKseh Fitting cover to go with a fascinating paper!

Ph2 multicenter study 🇨🇳 evaluated induction TNT, short course RT (25 Gy/5 fx) + CAPOX + toripalimab, in 33 low rectal cancer pts (T2–3 N0, 100% pMMR) ✅72.7% complete response & 60.6% organ preservation,↑ QoL vs surgery. 15% regrowth/mets (1) all salvaged by curative TME.

💉mRNA Covid vaccines and cancer 🔵A study in @Nature this week showed: SARS-CoV-2 mRNA vaccines sensitize tumours to ICI 👉 https://t.co/wgkbqfreKs 🟠2 years ago we hypothesized that immune stimulation by mRNA covid vaccine may somewhat interact with MSI status of colon cancer

Women derive more benefit from physical activity than men with respect to reduction of cardiovascular risk and related mortality, and can achieve protection at lower levels of engagement. From ~85,000 participants, open-access (blue=men) https://t.co/gfaPgCna4o

More info on elinzanetant is available here: https://t.co/84bN9TK08k & https://t.co/OB7heevDfp & https://t.co/3DtgbY3ubp #MedTwitter #OncTwitter #bcsm #regulatory

📣 FDA has approved a new non-hormonal pill, elinzanetant, to treat #menopause symptoms. The med is an NK3 receptor antagonist that works on the brain’s “thermostat” to decrease hot flashes/night sweats from low estrogen. #bcsm #MedTwitter #regulatory 1/2 https://t.co/MNbhvHVYxs

DYNAMIC-III trial @NatureMedicine https://t.co/byJEUamKJU 👉 How to improve prognosis for ctDNA+ patients? 1️⃣ Intensive: CIRCULATE-US (FOLFIRINOX) 2️⃣ Sequential: CIRCULATE-Japan, ALTAIR (SOC then FTD/TPI) ➡️Favored, but statistically negative 3️⃣ Combination: PEGASAS #ESMO25

November 7th is the date! Join us for both of these events during lung cancer awareness month. We are stronger and united in this mission to end lung cancer in Mississippi. #lcsm @PierredeDelva1 @KelseyKochMD @rodrocconi @UMMC_Cancer @AmericanCancer Cc: @EGFRResisters

In a cohort of over 13,500 women with mean age ~72 years, >4,000 steps per day, at least 1-2 days per week, was associated with reduction in all-cause mortality and lower risk of cardiovascular disease https://t.co/4ATXqadPFp

How do mRNA vaccines help fight cancer? A @nature publication today tells the story, one with big implications, as reviewed here @MDAndersonNews @StevenLin_MDPhD @adam_grippin https://t.co/J0OvNP1Oc4

@5_utr TBD on what outcomes might have been without surgery... Cercek at a description of ~ 150 patients, but change takes time. I am inclined to agree though.

@GIMedOnc Some thoughts: 1. Agree surg may be omitted. Recurrence after CR rare based on trials in other stg IV cancers. 2. Toxicity of ipi/nivo is real. Balance of surg first and IO for recurrence, vs neoadjuv approach? 3. Surveillance schedule for non-op colon? Q6mo x3y seems reasonable.

Wow. 26% of MSS colorectal cancer patients showed some response to immunotherapy, and 20% had at least ten-fold reduction in tumor volume. Still Phase 2, but this could be transformative for CRC! Huge congrats to the team.